Bicycle Therapeutics director Charles Swanton resigns
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Bicycle Therapeutics plc (BCYC) reported that on August 18, 2026, Charles Swanton resigned, effective immediately, as a Class II director on the Board of Directors, as a member of the Board’s committees, and as a member of the company’s Clinical Advisory Board. The company states that Dr. Swanton resigned for personal reasons and that his resignation was not due to any disagreement with Bicycle Therapeutics regarding its operations, policies, or practices.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Figures
Resignation effective date: August 18, 2026
Report signature date: August 20, 2026
Ordinary share nominal value: £0.01 per share
3 metrics
Resignation effective date
August 18, 2026
Effective date of Charles Swanton’s resignation from all roles
Report signature date
August 20, 2026
Date Bicycle Therapeutics plc’s officer signed the current report
Ordinary share nominal value
£0.01 per share
Nominal value of each ordinary share of Bicycle Therapeutics plc
Key Terms
Class II director, Clinical Advisory Board, American Depositary Shares, Emerging growth company
4 terms
Class II director regulatory
"Charles Swanton resigned as a Class II director of the Board of Directors"
A class II director is a member of a company’s board who belongs to one of several staggered groups of directors, each group standing for election in different years. For investors, this matters because staggered terms slow wholesale board turnover—like rotating members of a neighborhood committee—making sudden changes in control or strategy harder and affecting how quickly shareholders can influence corporate direction.
Clinical Advisory Board medical
"and as a member of the Company’s Clinical Advisory Board, effective immediately"
A clinical advisory board is a group of independent medical and scientific experts a company consults to guide clinical development, trial design, regulatory strategy and product use. Like a navigation team advising a ship’s captain, they bring real‑world experience and credibility that can speed development, reduce regulatory and clinical risk, and influence investor confidence by signaling that the science and path to market are being thoughtfully managed.
Emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What Board change did Bicycle Therapeutics plc (BCYC) announce on August 18, 2026?
Bicycle Therapeutics plc announced that Charles Swanton resigned, effective August 18, 2026, as a Class II director, as a member of the Board’s committees, and from the company’s Clinical Advisory Board.
Why did Charles Swanton resign from the Board of Bicycle Therapeutics plc (BCYC)?
The company states that Charles Swanton resigned for personal reasons and that his resignation was not the result of any disagreement with Bicycle Therapeutics regarding its operations, policies, or practices.
Did Bicycle Therapeutics plc (BCYC) report any disagreement associated with Charles Swanton’s resignation?
No. Bicycle Therapeutics plc states that Dr. Swanton’s resignation was for personal reasons and not due to any disagreement with the company about its operations, policies, or practices.
What other roles did Charles Swanton leave at Bicycle Therapeutics plc (BCYC)?
In addition to his role as a Class II director, Charles Swanton resigned as a member of the Board’s committees and as a member of the company’s Clinical Advisory Board, all effective immediately on August 18, 2026.
Who signed the August 2026 current report for Bicycle Therapeutics plc (BCYC)?
The report was signed on behalf of Bicycle Therapeutics plc by Travis Thompson, who is identified as the company’s Chief Financial Officer, dated August 20, 2026.
AI-generated analysis. How Rhea-AI works. Not financial advice.
